linjc16/ctgov huggingface dataset:
Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation

Study Overview
=================
Brief Summary
-----------------
A major source of graft failure and dysfunction in lung transplantation is known to be bronchiolitis obliterans (BO)and its clinical correlate called bronchiolitis obliterans syndrome(BOS). In fact, BOS is the leading cause of death in lung recipients beyond one year post transplant. Currently, our ability to assess lung injury after transplant is less than ideal. The purpose of this study is to use new computerized tomography(CT) technology, specifically , 64 bit acquisition, to detect and predict the onset of lung injuries, with the hope of finding better therapies that currently exist.

Detailed Description
-----------------
Total enrollment : 10 Lung transplant patients will undergo CT Scans before scheduled bronchoscopies which are routinely performed at 1, 3, 6, 9, and 12 months post transplant. Imaging will be done with the newest generation scanner, with intent to analyze all pertinent areas of the lung for pathology, but especially the bronchial anastomoses, the lung parenchyma with focus on gas exchanging lobules of the lung, and any suspected abnormalities from physical exam, laboratory tests, or prior chest xray. CT imaging will precede bronchoscopy and biopsy so that CT interpretation will be unencumbered by changes due to the bronchoscopic procedure.

Official Title
-----------------
Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation. Can We Help Diagnose Acute Rejection and Better Predict Bronchiolitis Obliterans?

Conditions
-----------------
Bronchiolitis Obliterans Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lung transplant patients who are at least 18 years of age. All patients must be able to give written informed consent. Exclusion Criteria: Lung transplant patients who are unable to undergo a CT Scan. Lung transplant patients who are unable to give informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bronchiolitis Obliterans Syndrome
Ten-year Follow-up of Laser in Situ Keratomileusis in Patients 8 to 15 Years Old

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety, efficacy, predictability, and stability of laser in situ keratomileusis (LASIK) to correct high anisometropia in patients 8 to 15 years old in whom conventional treatments have failed.

Detailed Description
-----------------
Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.

Official Title
-----------------
Ten-year Follow-up of Laser in Situ Keratomileusis in Patients 8 to 15 Years Old

Conditions
-----------------
Anisometropia

Intervention / Treatment
-----------------
* Procedure: LASIK


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: High anisometropia (>3.50 D) Patients 8 to 15 years old Conventional treatments have failed Exclusion Criteria: Diabetes Autoimmune diseases Topographic abnormalities

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser. | Procedure: LASIK<br>* Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
LASIK, safety, efficacy, stability, high anisometropia, patients 8 to 15 years old, conventional treatments have failed
Monitoring of Cardiac Function With 3-axis Accelerometers

Study Overview
=================
Brief Summary
-----------------
Aim of the study: To validate accelerometers for continuous monitoring of global cardiac function during weaning from cardiopulmonary bypass (CPB) in cardiac surgery.

Detailed Description
-----------------
Hypothesis: The following hypothesis will be tested: Accelerometer measures are clinical relevant indices of global left and right myocardial performance during weaning from cardiopulmonary bypass. Model: The performance of the accelerometer will be tested in a intraoperative setting, during weaning from cardiopulmonary bypass. Accelerometer measures of ventricular systolic and diastolic function will be compared to corresponding measures and indices of ventricular functions by echocardiography and hemodynamic monitoring during a step wise controlled weaning from cardiopulmonary bypass, ensuring precise control of pre- and afterload.

Official Title
-----------------
Monitoring of Cardiac Function With 3-axis Accelerometers During Weaning of Cardiopulmonary by Pass After Heart Surgery

Conditions
-----------------
Heart; Surgery, Heart, Functional Disturbance as Result

Participation Criteria
=================
Eligibility Criteria
-----------------
The hypothesis will be tested in 20 elective patients. Inclusion Criteria: Significant aortic valvular disease scheduled to undergo cardiac surgery with an estimated extracorporeal circulation time > 40 min. Exclusion Criteria: Evolving myocardial infarction, dyskinetic wall motions, cardiogenic shock, hepatic dysfunction or esophageal disease.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of global heart function measures between accelerometer, echocardiography and hemodynamics. | Measures will be assessed at baseline before cardiopulmonary by pass, at different workloads during a stepwise weaning, and after the cannulas are removed. The accelerometer measurements will be compared to echocardiography and hemodynamics (stroke volume and cardiac output). Systolic global function will be assessed by comparing peak systolic velocity and displacement by the accelerometer and the corresponding findings in echocardiography. The accelerometer systolic measures will also be correlated to ejection fraction with echocardiography. Diastolic global function early inflow (E'), atrial inflow velocity (A') and E'/A' with accelerometers and echocardiography will be compared. | The patients will be followed during surgery, approximately 3 hours. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Accelerometer, Cardiopulmonary by pass
Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the effect of inhaled tiotropium bromide on trough FEV1 and to assess the cardiac effects through 12-lead and Holter ECG monitoring in patients with COPD.

Official Title
-----------------
Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With Chronic Obstructive Pulmonary Disease (a 12-week, Parallel Group, Randomized, Placebo-cotrolled, Double-blind Study).

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive

Intervention / Treatment
-----------------
* Drug: Tiotropium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History of COPD, FEV1 less than or equal to 65%, FEV1/FVC less than or equal 70% Smoking history greater than or equal to 10 pack years Not history of clinical diagnosis of asthma and/or atopy A history of thoracotomy with pulmonary resection Patients requiring the use of supplemental oxygen therapy for >12 hours per day Chronic use of systemic corticosteroids in an unstable daily dose Patients with a recent history of myocardial infarction A known hypersensitivity to anticholinergic drugs

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tiotropium|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Trough FEV1 after 12 weeks of treatment |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Trough FEV1 at Visit 3 |  | week 8 | 
| Trough FVC at Visits 3 and 4 |  | week 8 and week 12 | 
| FEV1 and FVC 90 min post study drug inhalation at all visits |  | 90 minutes post-medication | 
| Use of rescue medication |  | 12 weeks | 
| Patient's Global Evaluation |  | week 8 and week 12 | 
| Physician's Global Evaluation |  | week 8 and week 12 | 
| Health Related Quality of Life assessed by the EQ5D at Visit 2 and 4 |  | week 8 and week 12 | 
| Adverse events |  | 12 weeks | 
| Vital signs |  | week 8 and week 12 | 
| Physical Exam |  | week 12 | 
| 12-lead ECG |  | week 8 and week 12 | 
| 24-hour holter ECG monitoring |  | week 8 and week 12 |
Immunisation History Survey - a Study to Measure Levels of Immunity to Routine Immunisations

Study Overview
=================
Brief Summary
-----------------
To collect the immunisation history of participants enrolled in a previous vaccine study (REC 09/H0604/107) in order to assess the influence of genetic variation on the level of immunity to routine immunisations.

Detailed Description
-----------------
Children aged 6 month to 13 years were enrolled in a study to compare the immunogenicity and safety of adjuvanted or non-adjuvanted influenza vaccines during the 2009 pandemic influenza season. Nine-hundred and forty-nine children were recruited from 5 UK centres: Oxford, Southampton, Bristol, Exeter, and London In the previous study, DNA was collected when individuals provided appropriate consent, to explore the genetic determinants of responses to vaccination. Although, study participants consented for their medical records to be reviewed by members of the study team, and for these data as well as anonymised serum samples to be used in future research, routine immunisation histories were not collected before this study closed. In this study we wish to collect the full vaccination history of participants, as this information will be extremely important in interpreting results. We propose sending a letter to parents/guardians informing them of the study and asking whether they are willing for members of the study team to approach their general practitioner or the child health computer system in order to retrieve these records. Immunisation histories will then be included with other non-identifiable information needed for analysis, and samples unlinked from personal identifiers prior to analysis.

Official Title
-----------------
Immunisation History Survey - a Study to Measure Levels of Immunity to Routine Immunisations

Conditions
-----------------
Immunization; Infection

Intervention / Treatment
-----------------
* Other: Collection of vaccine histories


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The inclusion criteria are consent in the original vaccine study (09/H0604/107) with explicit consent for samples to be stored and used in future research as well as consent to this subsequent study Exclusion Criteria: Individuals who do not have explicit consent for samples taken in the original vaccine study (09/H0604/107) to be stored for future research. Individuals who have not been consented into this study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Collection of vaccine histories|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary endpoint will be the completion of the collection of vaccination histories from consented participants. |  | 1 year |
Quantitation of Glymphatic Functioning in Sleep and Meditative States

Study Overview
=================
Brief Summary
-----------------
This involves development and application of magnetic resonance imaging (MRI) methods for visualizing hemodynamic and metabolic relationships in healthy volunteers with advanced meditation experience.

Detailed Description
-----------------
This study is evaluating the glymphatic system during awake, sleep, and meditative states.

Official Title
-----------------
Quantitation of Glymphatic Functioning in Sleep and Meditative States

Conditions
-----------------
Parkinson Disease, Sleep

Intervention / Treatment
-----------------
* Behavioral: Meditation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 14-45 Adept meditator status Exclusion Criteria: Any non-MR compatible material implant, or contraindication to MR scanning Claustrophobia or inability to lie still for prolonged periods of time Participants with a recent (less than 2 months) infection, tattoo, or wound No consumption of stimulants or alcohol within 12 hours of the study visit clinical diagnosis of any major neurological or psychological condition Taking benzodiazepines, cholinestorase inhibitors, anti-psychotics, opioids, MAO inhibitors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Adept Meditators<br>Subjects will undergo scanning during awake, sleep deprived, and meditative states of consciousness. | Behavioral: Meditation<br>* meditation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CSF flow change | Using MRI to assess the change in CSF flow in awake, sleep deprived, and meditative states | baseline to 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EEG changes | Looking at brain wave changes before and after intervention in Alpha, Beta, and Delta waves associated with light to deep sleep. The lowest bandwidth for alpha waves is 8 while the highest is 12. The lowest bandwidth for Beta waves is 13 Hz while the highest is 30 Hz. The lowest bandwidth for Delta waves is .4 Hz and the highest is 4 Hz. | baseline to 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glymphatic system, meditation
Chest Radiography in COVID-19 Patients

Study Overview
=================
Brief Summary
-----------------
To assess the prognostic performance of the RALE score with respect to duration of ventilation, and to describe changes in the RALE score over time.

Official Title
-----------------
Radiographic Assessment of Lung Edema in Invasively Ventilated COVID-19 Patients (RALE-COVID) - Protocol for an International Multicenter Retrospective Study

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admitted to an ICU participating in this study between December 1, 2019 and May 31, 2020 Having had received invasive ventilation Having had received at least one chest radiograph under invasive ventilation Confirmed novel coronavirus diseases (COVID-19) Exclusion Criteria: - Age < 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The prognostic capacity of the Radiographic Assessment of Lung Edema (RALE) score of the first CXR under invasive ventilation in patients with severe COVID-19. |  | 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The prognostic capacity of changes in the RALE score of consecutive CXRs under invasive ventilation in patients with severe COVID-19 |  | 90 days | 
| Number of ventilator-free day and alive at day 28 (VFD) |  | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chest radiography, RALEscore, Radiographic Assessment of Lung Edema, ICU, invasively ventilated
Oxygen Therapy for Retinal Ischemia

Study Overview
=================
Brief Summary
-----------------
The investigators will be using nocturnal normobaric hyperoxia therapy in patients with diagnoses of conditions related to retinal ischemia.

Detailed Description
-----------------
Patients who receive a diagnosis of a condition relate to retinal ischemia and who pass the eligibility criteria will receive an oxygen concentrator to use at home. They will report back in follow up monthly for three to six months.

Official Title
-----------------
Normobaric Nocturnal Hyperoxia Therapy for Treating Ischemic-Related Retinal Conditions

Conditions
-----------------
Retinal Ischemia

Intervention / Treatment
-----------------
* Drug: Hyperoxia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of retinal-ischemia related condition Exclusion Criteria: Complicating other ocular condition History of smoking or lung conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: O2 recieving<br>Patients who receive hyperoxia | Drug: Hyperoxia<br>* Patients will receive nocturnal normobaric hyperoxia therapy<br>* Other names: Nocturnal normobaric hyperoxia;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best Corrected Visual Acuity | Best Corrected Visual Acuity as measured by ETDRS chart | 6 months | 
| Macula Edema | Amount of ME present, as measured by OCT | 6 months |
Acunpuncture for Fibromyalgia Syndrome

Study Overview
=================
Brief Summary
-----------------
patients suffering from fibromyalgia syndrome according to the criteria of the American College of Rheumatology 2010 will be enrolled. All fibromyalgic patients will be subjected to a further ambulatory visit and if an energy deficiency in the Liver and Spleen Meridians will be identified, according to the Traditional Chinese Medicine rules, acupuncture will be planned. If not, a standard therapy with analgesic drugs will be started. Acupuncture treatment will consist of six weekly sessions. Tricyclic antidepressants, anti-epileptic drugs, selective serotonin reuptake inhibitors and opioids will be used as standard strategy. Pain Scores and Fatigue Impact Scale will be assessed before any treatment and after a 28 days follow-up.

Official Title
-----------------
Acupuncture for Fibromyalgia Syndrome: An Observational Parallel Groups Study

Conditions
-----------------
Acupuncture, Fibromyalgia

Intervention / Treatment
-----------------
* Procedure: Acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of Fibromyalgia Exclusion Criteria: coagulation disorders pregnancy pacemaker Implantable Cardioverter Defibrillator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Acupuncture Group<br> | Procedure: Acupuncture<br>* Acupuncture with disposable needles will be implemented<br>|
| No Intervention: Standard Therapy Group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Score | Numeric Rating Scale from 0 (absence of pain )to 10 (worst pain ) | 28 days after the completion of the treatment |